Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England
Morgan, Robert David
Burghel, G. J.
Clamp, Andrew R
Mitchell, Claire L
Woodward, E. R.
Crosbie, E. J.
Edmondson, R. J.
Wallace, A. J.
Jayson, Gordon C
Lalloo, F. I.
Harkness, E. F.
Evans, D. G. R.
AffiliationThe Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractPoly(ADP-ribose) polymerase (PARP) inhibitors improve survival in BRCA-mutant high-grade serous ovarian carcinoma. As a result, germline and somatic BRCA1/2 testing has become standard practice in women diagnosed with ovarian cancer. We outline changes in testing and detection rates of germline BRCA1/2 pathogenic variants (PVs) in cases of non-mucinous epithelial ovarian cancer diagnosed during three eras, spanning 12 years, within the North West of England, and compare the uptake of cascade testing in families identified by oncology-led mainstreaming versus regional genetics clinics. Eras included: Period 1 (20% risk threshold for testing): between January 2007 and May 2013; Period 2 (10% risk threshold for testing): between June 2013 and October 2017 and; Period 3 (mainstream testing): between November 2017 and November 2019. A total of 1081 women underwent germline BRCA1/2 testing between January 2007 and November 2019 and 222 (20.5%) were found to have a PV. The monthly testing rate increased by 3.3-fold and 2.5-fold between Periods 1-2 and Periods 2-3, respectively. A similar incidence of germline BRCA1/2 PVs were detected in Period 2 (17.2%) and Period 3 (18.5%). Uptake of cascade testing from first-degree relatives was significantly lower in those women undergoing mainstream testing compared with those tested in regional genetics clinics (31.6% versus 47.3%, P = 0.038). Mainstream testing allows timely detection of germline BRCA1/2 status to select patients for PARP inhibitors, but shortfalls in the uptake of cascade testing in first-degree relatives requires optimisation to broaden benefits within families.
CitationFlaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, et al. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet. 2020.
JournalEuropean Journal of Human Genetics
- Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases.
- Authors: Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR
- Issue date: 2019 May
- Uptake of testing for germline <i>BRCA</i> mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.
- Authors: Stearnes G, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Cohen PA
- Issue date: 2019 Jul
- A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
- Authors: Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N
- Issue date: 2017 Apr
- Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
- Authors: Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ
- Issue date: 2020 Mar 12
- Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
- Authors: Jorge S, McFaddin AS, Doll KM, Pennington KP, Norquist BM, Bennett RL, Pritchard CC, Swisher EM
- Issue date: 2020 Mar